Clinical Research Directory

Inclusion Criteria: * Healthy adults aged 18 to 50 years (inclusive) at the time of signing the informed consent form, of either sex. * Body weight ≥50 kg for males and ≥45 kg for females at screening; body mass index (BMI) within the range of 19.0 to 28.0 kg/m² (inclusive), calculated as body weight (kg) / height² (m²); vital signs, laboratory tests, and physical examination findings are either within normal limits or deemed clinically insignificant (abnormal without clinical relevance). * Best-corrected visual acuity (BCVA) ≥83 letters in both eyes (with refractive error ≤ -6.0 D); intraocular pressure (IOP) between 10 and 21 mmHg (inclusive) in both eyes, with an interocular IOP difference \<5 mmHg; ophthalmic examinations in both eyes (including BCVA, IOP, pupillary function, extraocular muscle motility, slit-lamp biomicroscopy, corneal fluorescein staining, and funduscopy after mydriasis) show no abnormalities, or any abnormalities present are clinically insignificant. * Ability and willingness to provide written informed consent, dated and signed personally, and to comprehend the study procedures and comply with all protocol requirements. * Agreement to practice effective contraception from the time of signing informed consent through 3 months after the last dose of study drug, and no plan to donate sperm or ova during this period. Exclusion Criteria: * Women who are pregnant or lactating. * History or presence of severe disorders of the cardiovascular, respiratory, hepatobiliary, digestive, urinary, renal, endocrine, immune, metabolic, or neuropsychiatric systems, or history of malignancy. * Anatomical abnormality in either eye or monocular vision; or any eyelid, ocular surface, or lacrimal drainage system abnormality deemed by the investigator to potentially affect drug absorption. * History of ocular disease in either eye that could affect visual function (e.g., glaucoma, retinal detachment, etc.), and considered by the investigator as unsuitable for trial participation. * Infectious, immune-mediated, or inflammatory ocular disease, or ocular trauma affecting either eye within 3 months prior to the first dose. * Clinically significant findings on ophthalmic examination at screening (e.g., conjunctival hyperemia grade ≥1, \>2 punctate corneal fluorescein staining spots, tear film break-up time \[TBUT\] \<10 seconds in both eyes, or other chronic or acute ocular pathologies). * History of intraocular surgery or ocular laser therapy. * Use of any ophthalmic medication (including eye drops or ophthalmic gels, etc.) within 1 month prior to screening. * Contact lens wear within 14 days prior to screening or during the clinical study period. * Positive test results at screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus (HIV) antibody/antigen, or syphilis serology. * History of drug allergy, particularly known allergy or idiosyncratic reaction to the investigational product or to any concomitant medications used during the study procedures. * Inability to tolerate venipuncture and/or history of vasovagal syncope (hemophobia or trypanophobia). * Prior treatment with any other nerve growth factor (NGF)-class agents; use of immunosuppressants or any other prescription medications within 4 weeks prior to the start of the study; use of traditional Chinese medicines, Chinese patent medicines, over-the-counter drugs, or dietary supplements within 2 weeks prior to the start of the study. (For drugs with a long half-life, a washout period of at least 5 half-lives is required.) * Participation in any other interventional clinical trial within 3 months prior to screening. * Vaccination within 1 month prior to screening, or planned vaccination during the study period. * Major surgery within 6 months prior to screening, or planned surgery during the study period. * History of drug abuse, positive urine drug screen, or current substance dependence. * Non-physiological blood loss ≥400 mL (including trauma, phlebotomy, or blood donation) within 3 months prior to the study, or receipt of any blood product transfusion; or blood donation within 3 months or planned blood donation during the study period; or blood sampling as a subject in another study within 3 months. * Average daily cigarette consumption \>5 cigarettes per day within 3 months prior to screening, or inability to refrain from smoking throughout the entire study period. * Suspected or confirmed alcohol dependence; average daily alcohol intake exceeding 2 units per day within 3 months (1 unit = 10 mL of pure ethanol, equivalent to 200 mL of beer at 5% alcohol, 25 mL of spirits at 40% alcohol, or 83 mL of wine at 12% alcohol); or positive alcohol breath test; or inability to abstain from alcohol during the study period. * Vital signs outside the following ranges: systolic blood pressure \<90 mmHg or ≥140 mmHg; diastolic blood pressure \<50 mmHg or ≥90 mmHg; pulse rate \<50 bpm or \>100 bpm. * Any other condition that, in the opinion of the investigator, would render the subject unsuitable for participation in the trial.